ClinicalTrials.gg
Not yet recruitingNCT06762548Updated Nov 2, 2026

Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia

A Phase 3 interventional study of DA-007 and Placebo in Chemotherapy Induced Alopecia and Chemotherapy Side Effects, sponsored by Applied Biology, Inc.. Not yet recruiting at 1 site in Italy. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Applied Biology, Inc. · Phase 3, Interventional, and Prevention

Updated Nov 2, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 13 studies in Alopecia by Applied Biology, Inc. — 3 open to participants now, 3 under way, 2 of them phase 3. Alopecia · Applied Biology, Inc..

Started
2027
with 2 others
Phase 3
3 of 13
1 open now
Registered
10th of 13
by date

Among the 13 studies in Alopecia by Applied Biology, Inc., this one is one of 3 that started in 2027, is one of 3 in phase 3, and was the 10th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 128 are open to participants now.

Browse Alopecia studies →

Open to participants now

3 of the 13 studies in Alopecia by Applied Biology, Inc. are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 76 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 48 (63%) stop at 75 or younger; 10 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Alopecia by Applied Biology, Inc., or all of them as a file.
02

Study summary

Clinical Study of DA-007 As a Treatment for Chemotherapy Induced Alopecia

Read the detailed description

Chemotherapy induced alopecia (CIA) is a common adverse event of oncological treatment. The significant psychological burden of CIA, particularly in women, leads some (\~8%) to reject life saving therapeutic regimens. Several studies have demonstrated the effectiveness of scalp vasoconstriction as a prophylactic treatment for CIA. Recently, US Food and Drug Administration (FDA) approved a scalp-cooling device as a prophylactic treatment for CIA. Scalp cooling results in reduced local blood perfusion and consequently reduced chemotherapeutic agents reaching the hair follicle niche; however, scalp cooling requires prolongation of the time required to attend the chemotherapy unit (>2 hrs) as well as common adverse events including intolerance to cold. A previous study demonstrated that the α1 agonist, phenylephrine hydrochloride, applied topically can penetrate the scalp and bind α1 receptors. As such, a topically applied α1 agonist would reduce scalp blood perfusion. A novel formula (DA-007), containing an α1 agonist, that can also penetrate the scalp and bind α1 receptors. The aim of the study is to test the hypothesis that DA-007 can reduce scalp blood perfusion and thus reduce hair loss due to chemotherapy.

03

Conditions studied

  • Chemotherapy Induced Alopecia
  • Chemotherapy Side Effects

Browse trials for

Keywords

  • Chemotherapy Induced Alopecia
  • Chemotherapy Alopecia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with stage I or stage II breast cancer
  • Scheduled but not begun, at least 4 cycles of taxane and/or anthracycline-based chemotherapy.
  • Ages 18-65
  • Able to give

Exclusion criteria

Exclusion Criteria:

  • Resting blood pressure outside the range of 105-140/ 55-99
  • Uncontrolled or severe hypertension
  • Female pattern hair loss or hair loss disorder
  • Folliculitis
  • Scalp psoriasis
  • Seborrheic dermatitis
  • Inflammatory scalp conditions such as lichen planopillaris
  • Subjects wearing wigs prior to chemotherapy
  • Use of MAO inhibitors
  • Unable to provide consent or make allotted clinical visits
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Active comparator
    DA-007

    Topical DA-007 Solution

    Drug: DA-007

  • Placebo comparator
    Placebo

    Topical Placebo Solution

    Drug: Placebo

Interventions

  • DrugDA-007

    Topical α1 agonist combination of Phenylephrine + Tyramine + Synephrine

  • DrugPlacebo

    Topical placebo solution

06

What researchers measure

Primary outcomes

  1. Prevention of Hair Loss (Common Terminology Criteria for Adverse Events V5.0)

    Amount of hair loss during chemotherapy treatment measured by the Common Terminology Criteria for Adverse Events (CTCAE) V5.0. The Common Terminology Criteria for Adverse Events is a common terminology developed by the National Cancer Institute to describe and grade adverse events related to cancer therapy.

    Time frame: Week [0,12]

Secondary outcomes

  1. Hair Re-Growth Post Treatment (Common Terminology Criteria for Adverse Events V5.0)

    Amount of hair re-growth post chemotherapy treatment measured by the Common Terminology Criteria for Adverse Events (CTCAE) V5.0. The Common Terminology Criteria for Adverse Events is a common terminology developed by the National Cancer Institute to describe and grade adverse events related to cancer therapy.

    Time frame: Week [12, 24]

07

Study locations

1 site
08

References and documents

Publications

  • Fahl WE. Complete prevention of radiation-induced dermatitis using topical adrenergic vasoconstrictors. Arch Dermatol Res. 2016 Dec;308(10):751-757. doi: 10.1007/s00403-016-1691-2. Epub 2016 Oct 4. PubMed 27704205 ↗
  • Soref CM, Fahl WE. A new strategy to prevent chemotherapy and radiotherapy-induced alopecia using topically applied vasoconstrictor. Int J Cancer. 2015 Jan 1;136(1):195-203. doi: 10.1002/ijc.28961. Epub 2014 May 16. PubMed 24811525 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2027; primary completion for Mar 2028, 5 months later.

Of 28 phase 3 interventional studies under Alopecia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 5 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Oct 2025 → Oct 2027, primary completion Sep 2026 → Mar 2028 and completion Nov 2026 → Nov 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 1, 2025
First posted
Jan 7, 2025
StartEst.
Oct 10, 2027was Oct 2025
Primary completionEst.
Mar 11, 2028was Sep 2026
CompletionEst.
Nov 6, 2028was Nov 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 10, 2025→Oct 10, 2027
Nov 2, 2026
Primary completion
Sep 11, 2026→Mar 11, 2028
Nov 2, 2026
Study completion
Nov 6, 2026→Nov 6, 2028
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Start date Oct 10, 2025→Oct 10, 2027
    Primary completion Sep 11, 2026→Mar 11, 2028
    Study completion Nov 6, 2026→Nov 6, 2028
    + 4 other changes: verification date, responsible party, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06762548
Collaborators
Daniel Alain, Inc., Follea International Limited
Responsible party
Sponsor
First posted
Jan 7, 2025
Start date
Oct 10, 2027 (estimated)
Primary completion
Mar 11, 2028 (estimated)
Completion
Nov 6, 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Andy Goren, MD
Contact
clinicalstudies@appliedbiology.com
16507040850
Andy Goren, MD
study director · University of Rome G. Marconi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion